Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells

Pigment Cell and Melanoma Research

Volumn 28, Issue 2, 2015, Pages 184-195

  Webster, Marie R ^a   Xu, Mai ^b   Kinzler, Kathryn A ^b   Kaur, Amanpreet ^a   Appleton, Jessica ^a   O'Connell, Michael P ^a   Marchbank, Katie ^a   Valiga, Alexander ^a   Dang, Vanessa M ^a   Perego, Michela ^a   Zhang, Gao ^a   Slipicevic, Ana ^a   Keeney, Frederick ^a   Lehrmann, Elin ^b   Wood, William ^b   Becker, Kevin G ^b   Kossenkov, Andrew V ^a   Frederick, Dennie T ^c   Flaherty, Keith T ^c   Xu, Xiaowei ^d   Herlyn, Meenhard ^a   Murphy, Maureen E ^a   Weeraratna, Ashani T ^a   more..

^a WISTAR INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRAF; Metastasis; Senescence; Therapy resistance; Wnt5A

Indexed keywords

BETA GALACTOSIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P21; SENESCENCE ASSOCIATED BETA GALACTOSIDASE; SENESCENCE ASSOCIATED HETEROCHROMATIC FOCI; UNCLASSIFIED DRUG; WNT5A PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ONCOPROTEIN; TUMOR MARKER; WNT PROTEIN; WNT5A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL AGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRESS; CHROMATIN; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MELANOMA CELL; MELANOMA CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; ANIMAL; CELL CLONE; FEMALE; MELANOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGICAL STRESS; SKIN TUMOR; TUMOR INVASION; TUMOR STEM CELL ASSAY;

ANIMALS; BIOMARKERS, TUMOR; CELL AGING; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; MELANOMA; MICE, NUDE; NEOPLASM INVASIVENESS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; SKIN NEOPLASMS; STRESS, PHYSIOLOGICAL; TUMOR STEM CELL ASSAY; WNT PROTEINS;

EID: 84923093613     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12330     Document Type: Article

References (34)

1. Acosta, J.C., and Gil, J. (2012). Senescence: a new weapon for cancer therapy. Trends Cell Biol. 22, 211-219.
2. Aird, K.M., Zhang, G., Li, H. et al. (2013). Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 3, 1252-1265.
3. Amaria, R.N., Lewis, K.D., and Jimeno, A. (2012). Vemurafenib: the road to personalized medicine in melanoma. Drugs Today (Barc.) 48, 109-118.
4. Anastas, J.N., Kulikauskas, R.M., Tamir, T. et al. (2014). Wnt5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J. Clin. Invest. 124, 2877-2890.
5. Biechele, T.L., Kulikauskas, R.M., Toroni, R.A., Lucero, O.M., Swift, R.D., James, R.G., Robin, N.C., Dawson, D.W., Moon, R.T., and Chien, A.J. (2012). Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci. Signal. 5, ra3.
6. Bissell, M. (2009). Mina Bissell: context is everything. [An interview by Ben Short]. J. Cell Biol. 185, 374-375.
7. Bitler, B.G., Nicodemus, J.P., Li, H. et al. (2011). Wnt5A suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 71, 6184-6194.
8. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426-3439.
9. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
10. Coppe, J.P., Desprez, P.Y., Krtolica, A., and Campisi, J. (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118.
11. Dissanayake, S.K., Wade, M., Johnson, C.E. et al. (2007). The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J. Biol. Chem. 282, 17259-17271.
12. Dissanayake, S.K., Olkhanud, P.B., O'Connell, M.P. et al. (2008). Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 68, 10205-10214.
13. Dorr, J.R., Yu, Y., Milanovic, M. et al. (2013). Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501, 421-425.
14. Eichhoff, O.M., Weeraratna, A., Zipser, M.C. et al. (2011). Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res. 24, 631-642.
15. Giuliano, S., Cheli, Y., Ohanna, M. et al. (2010). Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res. 70, 3813-3822.
16. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., and Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505.
17. Haferkamp, S., Becker, T.M., Scurr, L.L., Kefford, R.F., and Rizos, H. (2008). p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell 7, 733-745.
18. Haferkamp, S., Borst, A., Adam, C., Becker, T.M., Motschenbacher, S., Windhovel, S., Hufnagel, A.L., Houben, R., and Meierjohann, S. (2013). Vemurafenib induces senescence features in melanoma cells. J. Invest. Dermatol. 133, 1601-1609.
19. Haq, R., Fisher, D.E., and Widlund, H.R. (2014). Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin. Cancer Res. 20, 2257-2263.
20. Hayflick, L. (1974). The strategy of senescence. Gerontologist 14, 37-45.
21. Krejci, P., Prochazkova, J., Smutny, J., Chlebova, K., Lin, P., Aklian, A., Bryja, V., Kozubik, A., and Wilcox, W.R. (2010). FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone 47, 102-110.
22. Lleonart, M.E., Artero-Castro, A., and Kondoh, H. (2009). Senescence induction; a possible cancer therapy. Mol. Cancer. 8, 3.
23. Macip, S., Igarashi, M., Fang, L., Chen, A., Pan, Z.Q., Lee, S.W., and Aaronson, S.A. (2002). Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J. 21, 2180-2188.
24. Michaloglou, C., Vredeveld, L.C., Soengas, M.S., Denoyelle, C., Kuilman, T., van der Horst, C.M., Majoor, D.M., Shay, J.W., Mooi, W.J., and Peeper, D.S. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
25. O'Connell, M.P., Fiori, J.L., Baugher, K.M. et al. (2009a). Wnt5A activates the calpain-mediated cleavage of filamin A. J. Invest. Dermatol. 129, 1782-1789.
26. O'Connell, M.P., Fiori, J.L., Xu, M. et al. (2009b). The Orphan Tyrosine Kinase Receptor, ROR2, Mediates Wnt5A Signaling in Metastatic Melanoma. Oncogene 29, 34-44.
27. O'Connell, M.P., Marchbank, K., Webster, M.R. et al. (2013). Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discov. 3, 1378-1393.
28. Schmitt, C.A. (2003). Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat. Rev. Cancer 3, 286-295.
29. Schmitt, C.A., Fridman, J.S., Yang, M., Lee, S., Baranov, E., Hoffman, R.M., and Lowe, S.W. (2002). A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346.
30. Storey, J.D., and Tibshirani, R. (2003). Statistical significance for genomewide studies. Proc. Natl Acad. Sci. U.S.A. 100, 9440-9445.
31. Sun, C., Wang, L., Huang, S. et al. (2014). Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122.
32. Tai, A.W., and Chung, R.T. (2007). p53 restoration leads to tumor senescence and regression: implications for cancer therapy. Gastroenterology 133, 722-723.
33. Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, J.M. (2002). Wnt5A signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
34. Zhang, S. (2007). A comprehensive evaluation of SAM, the SAM R-package and a simple modification to improve its performance. BMC Bioinformatics 8, 230.